• Brightlands Venture Partners invested in Silicozyme, a Dutch biotech start-up developing technologies to simplify and scale protein manufacturing.
• The private funding round also included the Limburg Startup Capital Fund via LIOF.
• Proceeds target commercialization of Silicozyme’s integrated bioprocess platform, including a standardized downstream purification approach intended to cut cost and timelines.
• Silicozyme plans feasibility projects with industrial partners, starting in industrial biotechnology with an expansion path into biologics manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightlands Venture Partners BV published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.